1. Home
  2. CLX vs IONS Comparison

CLX vs IONS Comparison

Compare CLX & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clorox Company (The)

CLX

Clorox Company (The)

HOLD

Current Price

$85.97

Market Cap

12.4B

ML Signal

HOLD

Logo Ionis Pharmaceuticals Inc.

IONS

Ionis Pharmaceuticals Inc.

HOLD

Current Price

$75.12

Market Cap

11.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLX
IONS
Founded
1913
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.4B
11.9B
IPO Year
1994
1996

Fundamental Metrics

Financial Performance
Metric
CLX
IONS
Price
$85.97
$75.12
Analyst Decision
Hold
Strong Buy
Analyst Count
12
22
Target Price
$110.25
$93.36
AVG Volume (30 Days)
2.9M
1.6M
Earning Date
04-30-2026
04-29-2026
Dividend Yield
5.23%
N/A
EPS Growth
189.78
21.71
EPS
3.47
N/A
Revenue
$6,124,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.64
$77.99
P/E Ratio
$24.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$85.62
$31.67
52 Week High
$136.69
$86.74

Technical Indicators

Market Signals
Indicator
CLX
IONS
Relative Strength Index (RSI) 25.15 51.85
Support Level N/A $70.61
Resistance Level $127.24 $76.19
Average True Range (ATR) 2.67 2.35
MACD -1.18 0.17
Stochastic Oscillator 5.89 60.21

Price Performance

Historical Comparison
CLX
IONS

About CLX Clorox Company (The)

Since its inception more than 100 years ago, Clorox has expanded to operate in a variety of consumer product categories, including cleaning supplies, laundry care, trash bags, cat litter, charcoal, food dressings, water filtration products, and natural personal care products. Beyond its namesake brand, the firm's portfolio includes Liquid-Plumr, Pine-Sol, S.O.S, Tilex, Kingsford, Fresh Step, Glad, Hidden Valley, KC Masterpiece, Brita, and Burt's Bees. More than 80% of Clorox's sales come from its home turf.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Share on Social Networks: